NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
Clinical Trials
25 trialsNCT04967248 2025-12-04
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Novartis
Terminated
NCT05252416 2025-11-28
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04024436 2025-11-13
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Taiho Oncology, Inc.
Phase 2 Terminated
NCT05384119 2025-02-21
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Tvardi Therapeutics, Incorporated
Phase 1 Terminated
NCT04060862 2024-11-08
IPATunity150
Hoffmann-La Roche
Phase 1 Terminated
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT02964507 2024-08-29
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT01296555 2024-07-31
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Terminated
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT05065411 2024-02-26
VERU-024
Veru Inc.
Phase 3 Terminated
NCT02761694 2023-05-06
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT02340221 2022-07-12
SANDPIPER
Hoffmann-La Roche
Phase 3 Terminated
NCT03584009 2022-06-28
Veronica
Hoffmann-La Roche
Phase 2 Terminated
NCT03220178 2022-01-06
PRECYCLE
Palleos Healthcare GmbH
Phase 4 Terminated
NCT04031885 2021-08-24
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Eli Lilly and Company
Phase 4 Terminated
NCT03134638 2021-03-09
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Syros Pharmaceuticals
Phase 1 Terminated
NCT03241810 2020-09-02
SHERBOC
Elevation Oncology
Phase 2 Terminated
NCT01633060 2019-01-30
BELLE-3
Novartis
Phase 3 Terminated
NCT02374099 2018-12-14
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Celgene
Phase 2 Terminated
NCT00752986 2016-12-05
ZACFAST
Sanofi
Phase 2 Terminated
NCT01528345 2016-07-11
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Novartis
Phase 2 Terminated
NCT01233947 2012-01-09
Study of AFP464 +/- Faslodex in ER + Breast Cancer
Tigris Pharmaceuticals
Phase 2 Terminated
NCT00774878 2011-03-03
Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
Sanofi
Phase 2 Terminated